CD68, also known as macrosialin in mice, is a member class D scavenger receptors. It is a glycosylated type I membrane protein, which is expressed in mononuclear phagocytes and other macrophages. CD68 is transcendently communicated in endosomes and lysosomes of macrophages and found on the outside of DCs and osteoclasts. CD68 has been broadly utilized as a pan-macrophage marker. High thickness of CD68+ TAMs is associated with high stromal and serum levels of VEGF. Regulation of VEGF in macrophages by IR is known to diminish the antitumor viability of radiotherapy. Additionally, CD68 is widely used as an indicator for malignancy forecast.
COVID-19 Impact Analysis
- Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global CD68 market.
Top Impacting Factors
Increase in research and development centers for development of disease prevention mechanisms and diabetic therapeutic medications coupled with rising awareness on CD68 and presence of higher population base in India and China are anticipated to drive market growth.
Additionally, favorable reimbursement policies coupled with supportive regulatory norms in countries such as India and Singapore are further anticipated to drive market growth.
However, stringent regulations in fragile economies such as Cuba and Vietnam coupled with low per capita income is anticipated to hamper market growth in these regions.
Additionally, higher costs associated with laboratory research pertaining to CD68 may further hamper market growth of CD68 market.
Key Market Trends
- North America is anticipated to dominate the market, owing to rising number of chronic diseases in the region coupled with growing underlying demand for advanced therapeutic medications and rise in government spending in biotechnology research and development.
- Europe exhibits huge growth potential for CD68 due to prevalence of tumors and bosom malignancy in the region coupled with presence of highly industrialized economies in the region, which benefit from the higher disposable incomes.
- Asia-Pacific is anticipated to witness exponential growth, owing to improving medical care foundation, bringing down administrative obstacles, and expanding research and development ventures in the region.
- Latin American is anticipated to witness constant growth, owing to rise in government spending in the medical services industry coupled with rise in awareness of biotechnology and associated fields.
- Middle East and Africa are expected witness stagnant growth, due to lack of research and development facilities in the region, lack of medical infrastructure coupled with fragile legal and economic condition, and less awareness on biotechnology.
Key Benefits of the Report
- This study presents the analytical depiction of the CD68 industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the CD68 Market share.
- The current market is quantitatively analyzed to highlight market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the CD68 Market Report
- Which are the leading players active in the CD68 market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the CD68 market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 in the industry?
- What is CD68 market?
- What is the CD68 market prediction in the future?
- What are the current trends and predicted trends?
CD68 Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Application |
|
 By Region |
|
 Key Market Players | Biosensis, Bioss Antibodies, Novus Biologicals, Bio-Rad, Atlas Antibodies, BethylLaboratories, Aviva Systems Biology Corporation, Abbexa Ltd, St John's Laboratory Ltd., Rockland, EnzoLifeSciences, Epigentek,, RandD Systems, Boster Biological Technology, Biobyt, Genetex, Lifespan Biosciences, ProteoGenix, Stemcell, ProSci, Proteintech, BioVision, Abiocode, BioLegend |
Loading Table Of Content...
